Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2021-11-11 AGM Information
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Chair's Address to the 2021 Annual General Meeting 4 pages 278.2KB
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting – Chair Address' and is dated 12 November 2021. It is addressed to shareholders and contains a detailed message from the Chair discussing the company's achievements, future outlook, and ongoing projects. The content focuses on the company's strategy, progress, and acknowledgments to the board and management, typical of communications made during an AGM. There is no detailed financial data or comprehensive financial statements present, which would be expected in an Annual Report (10-K) or Interim Report (IR). The document is not a transcript of a call, nor does it announce voting results or capital changes. It is a presentation or address made at the Annual General Meeting, consistent with the AGM Information category. The length of the document (12,695 characters) supports it being a substantive communication rather than a brief announcement. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-11-11 English
AGM Presentation 51 pages 3.4MB
AGM Information Classification · 95% confidence The document is a detailed presentation titled 'Annual General Meeting November 2021' and contains extensive information about the company's achievements, scientific advisory board, clinical trials, strategic reviews, and future plans. It includes forward-looking statements, detailed descriptions of therapies, clinical trial progress, and business development activities. The content is structured as a presentation with slides and images, typical of materials shared during an Annual General Meeting (AGM). There is no indication that this is a full annual report (10-K), earnings release, or regulatory filing. The document is not a brief announcement or voting result but a comprehensive presentation for shareholders and investors at the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-11-11 English
Results of Annual General Meeting 2 pages 284.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is dated 12 November 2021 and is addressed to the ASX Limited Market Announcements Office. It explicitly states it is the "RESULTS OF 2021 ANNUAL GENERAL MEETING" and provides detailed voting results for resolutions passed at the AGM, including adoption of remuneration report, re-election of a director, and approval of share issuance facilities. The document references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which govern disclosure of voting results. The content is focused solely on the announcement of voting outcomes from the AGM, not the AGM materials or the full annual report. The document length is 4064 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-11-11 English
Notification regarding unquoted securities - PTX 7 pages 30.1KB
Share Issue/Capital Change Classification · 95% confidence The document is a notification regarding the issue of unquoted equity securities, specifically unlisted options issued under an employee incentive scheme. It includes details such as the number of securities issued, issue date, security descriptions, and compliance with ASX listing rules. The document is an announcement of a securities issuance event rather than a financial report or detailed analysis. It does not contain financial statements or management discussion, nor is it a regulatory certification or voting result. The content aligns with announcements about share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support this classification with high confidence.
2021-11-04 English
Application for quotation of securities - PTX 6 pages 27.9KB
Capital/Financing Update Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a formal announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather a capital/financing update regarding securities quotation. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-11-03 English
September 2021 Quarterly Activities and Appendix 4C 10 pages 429.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'September 2021 Activities Report and Appendix 4C' and contains detailed quarterly financial and operational updates, including cash flow statements, clinical trial progress, and scientific advisory board changes. It reports on the quarter ended 30 September 2021, consistent with a quarterly reporting period. The presence of the Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, further confirms this is a quarterly financial report. The document includes substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2021-10-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.